Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis

NCT02495766 is registered in ClinicalTrials.gov with Banc de Sang i Teixits as lead sponsor.

NCT NCT02495766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02495766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis
Lead sponsor
Banc de Sang i Teixits
Phase
Phase 1/2
Overall status
Completed
Start date
May 11, 2015
Completion date
November 15, 2018
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis